by Fadi Agour, J.D. | Jan 14, 2026 | All Posts
Find out what’s happening with Talc cases and how firms can still profit from ongoing leads. The landscape of the Talcum Powder litigation—specifically the claims against Johnson & Johnson—has been completely reshaped. After years of legal maneuvering designed to...
by Fadi Agour, J.D. | Jan 9, 2026 | All Posts
Optimizing Mass Tort Intake to Maximize ROI Law firms invest millions into mass tort lead generation, using sophisticated ads across TV, social media, and search. Yet, the high volume of leads rarely translates directly into an equally high volume of signed retainers....
by Fadi Agour, J.D. | Jan 4, 2026 | All Posts, Blogs
The State of the Docket: Is There Still Opportunity? After years of massive, high-profile settlements—with Bayer allocating billions of dollars to resolve roughly 100,000 claims—many law firms assume the Roundup litigation is finally winding down. Here’s the reality:...
by Fadi Agour, J.D. | Dec 28, 2025 | All Posts, Blogs
The New Mass Tort Challenge: Sensitivity Meets Scale The Hair Relaxer litigation—centered on allegations that chemicals like endocrine-disrupting chemicals (EDCs) found in common products are linked to serious hormone-sensitive cancers—is one of the fastest-growing...
by Fadi Agour, J.D. | Dec 24, 2025 | All Posts, Blogs, Client Acquisition
The Cost of Low Quality: Why Bad Leads are Worse Than No Leads The acquisition of mass tort leads is now more competitive and expensive than ever. As the Estimated CPL (Cost Per Lead) for emerging dockets climbs, chasing volume over mass tort lead quality is the...
by Fadi Agour, J.D. | Dec 20, 2025 | All Posts, Blogs, Client Acquisition
The New Mass Tort Economics: Why Case Quality is the Only Metric that Matters For law firms focused on mass torts, 2025 is less about chasing volume and more about securing verified case quality. As the cost of acquisition rises and regulatory scrutiny...
